Pharma To Date

Inflammatix has recently raised $57 million in venture capital funding as it awaits FDA approval for its groundbreaking infectious disease diagnostic, the TriVerity test. This new test, designed to rapidly profile the body’s immune response, could transform the management of acute infections and sepsis in emergency settings.

The TriVerity test, a cartridge-based system that delivers results in approximately 30 minutes, aims to assist clinicians in distinguishing between bacterial and viral infections and identifying patients at risk for sepsis. This is particularly critical given that sepsis remains a leading cause of hospital mortality and represents one of the costliest diagnoses among Medicare beneficiaries.

Inflammatix’s funding will facilitate the expansion of its commercial team and support health economic studies to evaluate the test's potential impact on healthcare delivery. The TriVerity test uses advanced molecular techniques, including analysis of messenger RNA (mRNA) segments and artificial intelligence (AI) to detect early signs of infection. This approach promises to enhance early sepsis detection by identifying RNA changes in immune cells before clinical symptoms manifest, potentially enabling earlier and more effective intervention.

The company’s innovative approach has garnered attention due to its potential to address the limitations of existing diagnostics, which often fail to detect sepsis at an early enough stage to prevent severe outcomes. By leveraging machine learning and AI, TriVerity could significantly improve compliance with sepsis detection and treatment protocols, optimizing patient outcomes and hospital performance.

This funding round, led by Khosla Ventures and Think.Health, among other prominent investors, underscores the high expectations for the TriVerity test. Inflammatix also plans to develop a version of the test for use in emergency rooms, pending future regulatory approvals.

Overall, the advancement represented by the TriVerity test could mark a significant step forward in the fight against sepsis and other severe infections, offering a much-needed tool for timely and accurate diagnosis in emergency settings.